Heartland Bank & Trust Co Has $1.48 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Heartland Bank & Trust Co lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,158 shares of the company’s stock after buying an additional 248 shares during the period. Johnson & Johnson comprises approximately 0.8% of Heartland Bank & Trust Co’s investment portfolio, making the stock its 22nd biggest position. Heartland Bank & Trust Co’s holdings in Johnson & Johnson were worth $1,484,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of JNJ. McAdam LLC grew its stake in shares of Johnson & Johnson by 20.3% in the third quarter. McAdam LLC now owns 7,621 shares of the company’s stock worth $1,235,000 after purchasing an additional 1,287 shares during the last quarter. RAM Investment Partners LLC grew its stake in shares of Johnson & Johnson by 4.3% in the third quarter. RAM Investment Partners LLC now owns 1,751 shares of the company’s stock worth $284,000 after purchasing an additional 72 shares during the last quarter. Fulcrum Capital LLC boosted its position in Johnson & Johnson by 2.7% during the third quarter. Fulcrum Capital LLC now owns 3,698 shares of the company’s stock valued at $599,000 after acquiring an additional 96 shares during the last quarter. Wallington Asset Management LLC boosted its position in Johnson & Johnson by 3.4% during the third quarter. Wallington Asset Management LLC now owns 88,324 shares of the company’s stock valued at $14,314,000 after acquiring an additional 2,889 shares during the last quarter. Finally, Eagle Bay Advisors LLC boosted its position in Johnson & Johnson by 2.3% during the third quarter. Eagle Bay Advisors LLC now owns 5,042 shares of the company’s stock valued at $817,000 after acquiring an additional 114 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Stock Down 1.3 %

Johnson & Johnson stock opened at $163.67 on Friday. The firm has a 50 day simple moving average of $163.29 and a 200 day simple moving average of $154.92. The firm has a market capitalization of $393.90 billion, a price-to-earnings ratio of 10.20, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.66 EPS. On average, analysts predict that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.